DYSLIPIDEMIAS. PATHOPHYSIOLOGY, EVALUATION AND MANAGEMENT

1.Lipoprotein Physiology
2.Epidemiology of Blood Lipids and Lipoproteins
3.Lipoprotein(a)
4.Lipoproteins and Cardiovascular Disease Risk
5.Detection and Treatment of Children and Adolescents with Dyslipidemia
6.Type 2 Diabetes Mellitus and Dyslipidemia
7.Type 1 Diabetes Mellitus and Dyslipidemia
8.Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome
9.Dyslipidemia in HIV-Infected Patients
10.Monogenic Hypercholesterolemias
11.Primary Hypertriglyceridemia
12.Genetic Disorders of HDL Metabolism
13.Sitosterolemia and Other Rare Sterol Disorders
14.Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia
15.Drug-Induced Dyslipidemia
16.Lipodystrophies and Dyslipidemias
17.Novel Genes for Dyslipidemias: Genome-Wide Association Studies
18.Perspectives on Cholesterol Guidelines
19.Nutrition and Coronary Heart Disease Prevention
20.Phytosterol Therapy
21.N-3 Fatty Acids
22.Polyphenols for Cholesterol Management
23.Dietary Supplements for Cholesterol Management
24.Statins: Risk-Benefits and Role in Treating Dyslipidemias
25.Fibrates: Risk Benefits and Role in Treating Dyslipidemias
26.Niacin: Risk Benefits and Role in Treating Dyslipidemias
27.Bile Acid Sequestrants: Risk–Benefits and Role in Treating Dyslipidemias
28.Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias
29.Low-Density Lipoprotein (LDL) Apheresis
30.Novel Lipid-Lowering Agents

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.

Author
Abhimanyu Garg, MBBS, MD
Professor of Internal Medicine
UT Southwestern Medical Center
Department of Internal Medicine
5323 Harry Hines Blvd
Dallas, TX 75390
TEL 214-648-2895